Insights
Search Results
Client Highlights
1.12.26
Wilson Sonsini Advises on Juvena Therapeutics on IP Matters Related to $33.5 Million Series B
On January 12, 2026, Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, announced its $33.5 million Series B. The financing round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray. Wilson Sonsini Goodrich & Rosati advised Juvena on IP matters related to the transaction.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
11.18.25
Firm Advises ABL Bio on Strategic Alliance and Equity Investment with Eli Lilly
On November 14, 2025, ABL Bio announced a broad strategic research and development alliance with Eli Lilly and Company, establishing a multi-program collaboration to advance next-generation therapeutics using ABL Bio’s Grabody Platform. Wilson Sonsini Goodrich & Rosati advised ABL Bio on the license, research, and collaboration agreement, which is valued at up to $2.602 billion, including a $40 million upfront payment. Through this partnership, ABL Bio and Lilly will jointly explore and develop multiple therapeutic modalities across a range of disease areas, marking a significant expansion of ABL Bio’s platform-driven global collaborations.
Client Highlights
9.04.25
Wilson Sonsini Advises Foresight on Roche Settlement and Licensing Agreement
On August 29, 2025, Foresight Diagnostics, a privately held cancer diagnostics company and CLIA-registered laboratory, announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, Roche) involving Foresight’s patented PhasED-Seq™ technology. The agreement resolves litigation between the parties, with all claims against Foresight, its founders, and Stanford University dismissed with prejudice. Wilson Sonsini Goodrich & Rosati advised Foresight on the settlement and licensing agreement.
Client Highlights
7.02.25
Firm Advises Juvena on $650 Million Research Collaboration with Eli Lilly
On June 11, 2025, Juvena Therapeutics, Inc., a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company to discover, develop, and commercialize drug candidates that improve muscle health and body composition. Wilson Sonsini Goodrich & Rosati advised Juvena Therapeutics on the transaction.
Client Highlights
4.16.25
Wilson Sonsini Advises ABL Bio on Worldwide Licensing Agreement with GSK
On April 6, 2025, ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities to address significant unmet medical needs of patients suffering from neurodegenerative conditions. Wilson Sonsini Goodrich & Rosati is advising ABL Bio on the transaction.
Client Highlights
2.27.25
Wilson Sonsini Advises Cyrano Therapeutics on Option Agreement with KYORIN
On February 18, 2025, Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced that it entered into an option agreement with KYORIN Pharmaceutical. Under the agreement, KYORIN has an option to license CYR-064 for development and commercialization in Japan and will pay an option fee. Upon exercising the option and entering into a licensing agreement, KYORIN will provide Cyrano with an upfront payment, milestone payments tied to the progress of developing and commercializing CYR-064, and royalties based on a specified percentage of net sales following its launch. Wilson Sonsini Goodrich & Rosati advised Cyrano on the transaction.
Client Highlights
2.19.25
Firm Advises Novo Holdings on Investment in Newleos Therapeutics’ $93.5 Million Series A
On February 13, 2025, Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, announced the closing of an oversubscribed $93.5 million Series A financing. The financing was led by Goldman Sachs Alternatives with participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital. Wilson Sonsini advised Novo Holdings A/S on the transaction.
Client Highlights
10.03.24
Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd
On October 1, 2024 Aytu BioPharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics, and Lupin Pharma Canada Ltd, a subsidiary of global pharma major Lupin Limited, announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT® and Cotempla XR-ODT® product lines in Canada. Wilson Sonsini Goodrich & Rosati advised Aytu BioPharma on the transaction.
Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. Cotempla XR-ODT is the only extended-release orally disintegrating tablet methylphenidate and is FDA-approved as a once-daily ADHD treatment for patients 6 to 17 years of age. Aytu's ADHD portfolio has experienced rapid growth over the past two years, with prescriptions increasing 16.5 percent during that time. This agreement extends Aytu's reach through the expansion into one of the world's largest ADHD markets outside the United States. In 2023, the Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales. (Source: IQVIA Canada). Lupin will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT, which is expected to occur over the next 18 to 24 months.
Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. Cotempla XR-ODT is the only extended-release orally disintegrating tablet methylphenidate and is FDA-approved as a once-daily ADHD treatment for patients 6 to 17 years of age. Aytu's ADHD portfolio has experienced rapid growth over the past two years, with prescriptions increasing 16.5 percent during that time. This agreement extends Aytu's reach through the expansion into one of the world's largest ADHD markets outside the United States. In 2023, the Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales. (Source: IQVIA Canada). Lupin will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT, which is expected to occur over the next 18 to 24 months.
Client Highlights
9.26.24
Wilson Sonsini Advises Vertos Medical Inc. in Acquisition by Stryker
On August 22, 2024, Stryker, a global leader in medical technologies, announced a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Wilson Sonsini Goodrich & Rosati advised Vertos on the transaction.
Client Highlights
9.18.24
Firm Advises Ripple Therapeutics on Collaboration and Option-to-License Agreement with AbbVie
On September 17, 2024, Ripple Therapeutics announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next-generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform. Wilson Sonsini Goodrich & Rosati advised Ripple on the transaction.
Client Highlights
5.02.24
Firm Advises Novo Holdings on Reunion Neuroscience’s $103 Million Series A
On May 2, 2024, Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, announced the close of a $103 million Series A financing co-led by Novo Holdings and MPM BioImpact, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.